BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Steven M. Kornblau et al.|Cancer Cell|2014Cited by 366
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashionWilliam L. Heaton, Michael W. Deininger, Anna V. Senina et al.|Leukemia|2018Cited by 51
Nuclear–Cytoplasmic Transport Is a Therapeutic Target in MyelofibrosisDongqing Yan, Michael W. Deininger, Anthony D. Pomicter et al.|Clinical Cancer Research|2018Cited by 40
Supplementary Figure 3 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in MyelofibrosisDongqing Yan, Michael W. Deininger, Anthony D. Pomicter et al.|Unknown|2023Cited by 0
Supplementary Figure 3 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in MyelofibrosisDongqing Yan, Michael W. Deininger, Anthony D. Pomicter et al.|Unknown|2023Cited by 0